Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)
Israel · Delayed Price · Currency is ILS · Price in ILA 76.30
0.00 (0.00%)
Sep 3, 2026, 9:59 AM IDT
Novolog (Pharm-Up 1966) Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,815 | 1,805 | 2,022 | 1,643 | 1,508 | 1,255 | |
Revenue Growth | -10.98% | -10.70% | 23.01% | 8.99% | 20.13% | 10.73% |
Cost of Revenue | 1,658 | 1,650 | 1,837 | 1,470 | 1,328 | 1,101 |
Gross Profit | 156.13 | 155.83 | 184.95 | 173.76 | 179.7 | 154.67 |
Selling, General & Admin | 108.59 | 114.53 | 115.04 | 123.29 | 101.59 | 83.71 |
Other Operating Expenses | 1.94 | -4.48 | -2.79 | -3.49 | 0.31 | 1.55 |
Operating Expenses | 110.53 | 110.05 | 112.25 | 119.8 | 101.89 | 85.26 |
Operating Income | 45.59 | 45.78 | 72.7 | 53.97 | 77.81 | 69.41 |
Interest Expense | -25 | -19.27 | -12.61 | -12.87 | -12.54 | -8.47 |
Interest & Investment Income | 5.4 | 5.4 | 12.9 | 12.02 | 5.54 | 2.5 |
Earnings From Equity Investments | 0.9 | 1.26 | -0.44 | -30.64 | -4.61 | -1.64 |
Currency Exchange Gain (Loss) | -4.62 | -4.62 | -0.72 | -0.07 | 1.36 | -0.97 |
Other Non Operating Income (Expenses) | 0.85 | - | -3.79 | - | - | -1.22 |
EBT Excluding Unusual Items | 23.12 | 28.55 | 68.04 | 22.4 | 67.55 | 59.6 |
Impairment of Goodwill | -7.15 | -7.15 | -7.58 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -0.5 | - | - |
Gain (Loss) on Sale of Assets | 0.33 | 0.33 | 0.17 | -0.14 | 0.34 | 0.53 |
Asset Writedown | - | - | -2.95 | -50.67 | - | - |
Other Unusual Items | -14.9 | -14.9 | - | - | - | - |
Pretax Income | 1.4 | 6.83 | 57.68 | -28.91 | 67.89 | 60.13 |
Income Tax Expense | 2.02 | 2.33 | 16.69 | 10.47 | 16.98 | 15.31 |
Earnings From Continuing Operations | -0.62 | 4.5 | 41 | -39.39 | 50.91 | 44.83 |
Minority Interest in Earnings | -0.05 | -0.38 | -1.46 | -2.62 | -3.4 | -2.51 |
Net Income | -0.67 | 4.12 | 39.54 | -42 | 47.51 | 42.32 |
Net Income to Common | -0.67 | 4.12 | 39.54 | -42 | 47.51 | 42.32 |
Net Income Growth | - | -89.59% | - | - | 12.27% | 5.62% |
Shares Outstanding (Basic) | 511 | 511 | 511 | 510 | 507 | 505 |
Shares Outstanding (Diluted) | 511 | 511 | 511 | 511 | 516 | 515 |
Shares Change | 0.02% | 0.02% | -0.04% | -0.94% | 0.14% | 9.08% |
EPS (Basic) | -0.00 | 0.01 | 0.08 | -0.08 | 0.09 | 0.08 |
EPS (Diluted) | -0.00 | 0.01 | 0.08 | -0.08 | 0.09 | 0.08 |
EPS Growth | - | -89.54% | - | - | 12.20% | -3.53% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 65.92 | -18.45 | 145.12 | 163.77 | 87.68 | 52.75 |
Free Cash Flow Per Share | 0.13 | -0.04 | 0.28 | 0.32 | 0.17 | 0.10 |
Dividend Per Share | 0.039 | 0.039 | 0.049 | 0.029 | 0.066 | 0.094 |
Dividend Growth | 99.95% | -20.02% | 66.66% | -55.24% | -30.00% | 262.10% |
Gross Margin | 8.60% | 8.63% | 9.15% | 10.57% | 11.92% | 12.32% |
Operating Margin | 2.51% | 2.54% | 3.60% | 3.28% | 5.16% | 5.53% |
Profit Margin | -0.04% | 0.23% | 1.96% | -2.56% | 3.15% | 3.37% |
Free Cash Flow Margin | 3.63% | -1.02% | 7.18% | 9.96% | 5.81% | 4.20% |
EBITDA | 70.17 | 77.3 | 104.47 | 135.35 | 102.12 | 91.66 |
EBITDA Margin | 3.87% | 4.28% | 5.17% | 8.24% | 6.77% | 7.30% |
D&A For EBITDA | 24.57 | 31.52 | 31.77 | 81.38 | 24.32 | 22.25 |
EBIT | 45.59 | 45.78 | 72.7 | 53.97 | 77.81 | 69.41 |
EBIT Margin | 2.51% | 2.54% | 3.60% | 3.28% | 5.16% | 5.53% |
Effective Tax Rate | 144.49% | 34.18% | 28.93% | - | 25.01% | 25.45% |